JP2020536923A5 - - Google Patents

Download PDF

Info

Publication number
JP2020536923A5
JP2020536923A5 JP2020520587A JP2020520587A JP2020536923A5 JP 2020536923 A5 JP2020536923 A5 JP 2020536923A5 JP 2020520587 A JP2020520587 A JP 2020520587A JP 2020520587 A JP2020520587 A JP 2020520587A JP 2020536923 A5 JP2020536923 A5 JP 2020536923A5
Authority
JP
Japan
Prior art keywords
blinatumomab
pembrolizumab
variant
administered
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020520587A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536923A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/055667 external-priority patent/WO2019075366A1/en
Publication of JP2020536923A publication Critical patent/JP2020536923A/ja
Publication of JP2020536923A5 publication Critical patent/JP2020536923A5/ja
Priority to JP2023164647A priority Critical patent/JP2024001071A/ja
Pending legal-status Critical Current

Links

JP2020520587A 2017-10-13 2018-10-12 びまん性大細胞型b細胞リンパ腫を治療するための組成物及び方法 Pending JP2020536923A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023164647A JP2024001071A (ja) 2017-10-13 2023-09-27 びまん性大細胞型b細胞リンパ腫を治療するための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762571870P 2017-10-13 2017-10-13
US62/571,870 2017-10-13
PCT/US2018/055667 WO2019075366A1 (en) 2017-10-13 2018-10-12 COMPOSITIONS AND METHODS FOR TREATING DIFFUSED LYMPHOMA WITH LARGE B CELLS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023164647A Division JP2024001071A (ja) 2017-10-13 2023-09-27 びまん性大細胞型b細胞リンパ腫を治療するための組成物及び方法

Publications (2)

Publication Number Publication Date
JP2020536923A JP2020536923A (ja) 2020-12-17
JP2020536923A5 true JP2020536923A5 (cg-RX-API-DMAC7.html) 2021-11-18

Family

ID=64110107

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020520587A Pending JP2020536923A (ja) 2017-10-13 2018-10-12 びまん性大細胞型b細胞リンパ腫を治療するための組成物及び方法
JP2023164647A Pending JP2024001071A (ja) 2017-10-13 2023-09-27 びまん性大細胞型b細胞リンパ腫を治療するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023164647A Pending JP2024001071A (ja) 2017-10-13 2023-09-27 びまん性大細胞型b細胞リンパ腫を治療するための組成物及び方法

Country Status (15)

Country Link
US (1) US20200262919A1 (cg-RX-API-DMAC7.html)
EP (1) EP3694520A1 (cg-RX-API-DMAC7.html)
JP (2) JP2020536923A (cg-RX-API-DMAC7.html)
KR (1) KR20200068655A (cg-RX-API-DMAC7.html)
CN (1) CN111212646A (cg-RX-API-DMAC7.html)
AU (1) AU2018347457A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020007203A2 (cg-RX-API-DMAC7.html)
CA (1) CA3075291A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020000973A1 (cg-RX-API-DMAC7.html)
EA (1) EA202090565A1 (cg-RX-API-DMAC7.html)
IL (1) IL273805A (cg-RX-API-DMAC7.html)
MX (2) MX2020003395A (cg-RX-API-DMAC7.html)
SG (1) SG11202002374RA (cg-RX-API-DMAC7.html)
TW (1) TW201922283A (cg-RX-API-DMAC7.html)
WO (1) WO2019075366A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
TW202200615A (zh) * 2020-03-12 2022-01-01 美商安進公司 用於治療和預防患者的crs之方法
WO2022081529A1 (en) * 2020-10-12 2022-04-21 Greffex, Inc. Antibody constructs to target t cell responses to sars-cov protein expressing cells, their design and uses
WO2024097218A1 (en) * 2022-11-01 2024-05-10 TeneoTwo, Inc. Methods of treating non-hodgkin lymphoma

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
CA2326389C (en) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
WO2008119565A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific binding domain
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
WO2016019969A1 (en) * 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Subcutaneously administered bispecific antibodies for use in the treatment of cancer
EP3302501B1 (en) 2015-05-29 2021-09-22 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer
KR20180023968A (ko) * 2015-07-02 2018-03-07 셀진 코포레이션 혈액암 및 충실성 종양의 치료를 위한 병용 요법

Similar Documents

Publication Publication Date Title
JP2015187157A5 (cg-RX-API-DMAC7.html)
JP2017503820A5 (cg-RX-API-DMAC7.html)
JP2017226708A5 (cg-RX-API-DMAC7.html)
JP2012193216A5 (cg-RX-API-DMAC7.html)
JP2017149726A5 (cg-RX-API-DMAC7.html)
JP2012518624A5 (cg-RX-API-DMAC7.html)
EA200800881A1 (ru) Лекарственная форма пирфенидона в виде капсул с фармацевтически приемлемыми эксципиентами
JP2017048208A5 (cg-RX-API-DMAC7.html)
JP2009545600A5 (cg-RX-API-DMAC7.html)
JP2018506550A5 (cg-RX-API-DMAC7.html)
JP2018505882A5 (cg-RX-API-DMAC7.html)
MY141025A (en) Dose forms
JP2018507243A5 (cg-RX-API-DMAC7.html)
JP2016515586A5 (cg-RX-API-DMAC7.html)
IL307992A (en) Parasitic formulations containing isoxazoline and methods for treating blepharitis
JP2006513184A5 (cg-RX-API-DMAC7.html)
JP2017512194A5 (cg-RX-API-DMAC7.html)
JP2012502103A5 (cg-RX-API-DMAC7.html)
JP2017537927A5 (cg-RX-API-DMAC7.html)
JP2015507020A5 (cg-RX-API-DMAC7.html)
JP2018506533A5 (cg-RX-API-DMAC7.html)
JP2017527551A5 (cg-RX-API-DMAC7.html)
JP2022512158A5 (cg-RX-API-DMAC7.html)
JP2010504307A5 (cg-RX-API-DMAC7.html)
RU2006132069A (ru) Противораковые терапии